Jazz Pharmaceuticals Announces Issuance of Additional Xyrem® Patent

     Jazz Pharmaceuticals Announces Issuance of Additional Xyrem® Patent

  PR Newswire

  DUBLIN, Dec. 4, 2012

DUBLIN, Dec. 4, 2012 /PRNewswire/ --Jazz Pharmaceuticals plc (Nasdaq: JAZZ)
today announced that the United States Patent and Trademark Office has issued
a patent related to the use of Xyrem® (sodium oxybate) oral solution for the
treatment of narcolepsy, titled "Microbiologically Sound and Stable Solutions
of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy." The new
patent, number 8,324,275, will be submitted for listing in the FDA's Approved
Drug Products With Therapeutic Equivalence Evaluations (the Orange Book).

"Our intellectual property, including the patent issued today, reflects the
company's continued commitment to the further understanding of Xyrem and to
supporting its safe and effective use," stated Bruce Cozadd, chairman and
chief executive officer of Jazz Pharmaceuticals.

In addition to the newly issued patent, ten other U.S. patents have previously
been issued related to Xyrem's stable and microbially resistant formulation,
its manufacturing process, and its method of use, including its restricted
distribution system. The new patent, which will expire in December 2019, would
be the ninth patent referencing Xyrem to be listed in the Orange Book. The
listed patents expire at various times from 2019 to 2024.

Xyrem is the only product approved by the United States Food and Drug
Administration for the treatment of both cataplexy and excessive daytime
sleepiness in patients with narcolepsy.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on
improving patients' lives by identifying, developing and commercializing
innovative products that address unmet medical needs. The company has a
diverse portfolio of products in the areas of narcolepsy, oncology, pain and
psychiatry. The company's U.S. marketed products in these areas include:
Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia
chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Luvox CR®
(fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of
the U.S., Jazz Pharmaceuticals also has a number of products marketed by its
international division, EUSA Pharma.

Contact: Ami Knoefler, Executive Director, Investor Relations & Corporate
Communications, Jazz Pharmaceuticals plc, Ireland, +353-1-638-1032, U.S.,
Press spacebar to pause and continue. Press esc to stop.